Beta-blockers in the third millennium - When are they really indicated?

Journal of Clinical and Basic Cardiology

Volumn 4, Issue 1, 2001, Pages 3-9

  Prichard, B N C ^a   Graham, B ^a   Cruickshank, J M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Beta blocker; Diabetes; Hypertension; Morbidity; Mortality

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; METOPROLOL; NIFEDIPINE; PINDOLOL; PRACTOLOL; PRONETALOL; PROPRANOLOL; SOTALOL; VERAPAMIL;

AGE; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLD STRESS; COMORBIDITY; DIABETES MELLITUS; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; EXERCISE TOLERANCE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW;

EID: 0035023023     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Beta blockers continue to surprise us
2. Carvedilol
3. Nebivolol in the management of essential hypertension
4. Treatment of acute myocardial infarction with propranolol
5. Hypotensive action of pronethalol in the treatment of hypertension
6. Discovery of the hypotensive effect of propranolol
7. Use of propranolol in angina pectoris
8. Assessment of propranolol in angina pectoris. Clinical dose response curve: The effect on electrocardiogram at rest and on exercise
9. Practolol in the treatment of hypertension
10. Effect of new beta blocking agent, atenolol (Tenormin), on pain frequency, trinitrin consumption, and exercise ability
11. Effect of partial agonist activity in beta-blockers in severe angina pectoris: A double blind comparison of pindolol and atenolol
12. Treatment of stable angina
13. The additive anti-anginal action of oral isosorbide dinitrate in patients receiving propranolol. Magnitude and duration of effect
14. Beta-adrenergic blockade in ischaemic disease
15. Comparison of nifedipine and isosorbide dinitrate when added to maximal propranolol therapy in stable angina pectoris
16. Optimum treatment of stable angina pectoris
17. Objective assessment of anti-anginal treatment: A double-blind comparison of propranolol, nifedipine and their combination
18. Comparison of controlled onset extended release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischaemia in patients with chronic stable angina pectoris
19. Combined therapy with verapamil and propranolol in chronic stable angina
20. Beneficial effects of diltiazem and propranolol, alone and in combination, in patients with stable angina pectoris
21. Clinical outcome studies of anti-anginal drug therapy for patients with stable coronary disease: An indication for clinical trials
22. Beta-blocking drugs and coronary heart disease
23. Management of stable angina pectoris
24. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery
25. Prognostic significance of transient ischemic episodes: Response to treatment shows improved prognosis
26. Beta-blockade during and after myocardial infarction: An overview of the randomised trials
27. Controlled trail of sotalol for 1 year after myocardial infarction
28. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
29. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the post-infarction period
30. b-Blockers and sudden cardiac death
31. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) phase II trial
32. Early treatment with thrombolysis and beta-blockade in suspected acute myocardial infarction: Results from the TEAHAT study
33. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
34. The effect of carvedilol on mortality in patients with chronic heart failure
35. Effect of beta-blockade on mortality among high-risk and low-risk patients with myocardial infarction
36. Use of propranolol in the treatment of hypertension
37. Beta adrenergic blockade in pheochromocytoma, thyrotoxicosis, mitral stenosis and shock
38. The sixth report the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI)
39. Guidelines for the management of hypertension: Report of the third working party of the British Hypertension Society
40. International society of hypertension guidelines for the management of hypertension
41. 1-selective blocking agents
42. Use of propranolol in conjunction with alpha-receptor blocking drugs in phaeochromocytoma
43. Single-drug therapy for hypertension in men. A comparison of six anti-hypertensive agents with placebo
44. Department of veterans affairs single-drug therapy for hypertension study: Revised figures and new data
45. Randomised double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine and enalapril in antihypertensive treatment: Results of the HANE study
46. Treatment of mild hypertension study: Final results
47. Antihypertensive efficacy of treatment regimens used in veterans administration hypertension clinics
48. Bisoprolol
49. Double-blind comparison of the cardio-selective-blockers bisoprolol and atenolol in hypertension: The Bisoprolol International Multicenter Study (BIMS)
50. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents
51. The rationale for combination versus single-entity therapy in hypertension
52. Newer approaches to antihypertensive therapy: Use of fixed-dose combination therapy
53. A multifactorial trial design to assess combination therapy in hypertension
54. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension
55. Low dose drug combination therapy: An alternative first-line approach to hypertension treatment
56. The impact of ethnicity on response to antihypertensive therapy
57. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis
58. Treatment of beta-blockers for the primary prevention of the cardiovascular complications of hypertension
59. MRC trial of treatment of mild hypertension principal results
60. Cardiovascular risk factors in a randomised trial of treatment based on oxprenolol
61. Beta blockers and cardioprotection - Is there any good news from the recent trials?
62. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial
63. Primary prevention with metoprolol in patients with hypertension: Mortality results from MAPHY study
64. Medical research council trial of treatment of hypertension in older adults: Principal results
65. Are b-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
66. Effects of antihypertensive drugs on large artery compliance
67. Clinical effects of b-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials
68. B-blockers in heart failure. The "new wave" clinical trials
69. B-blockers. The new standard of therapy for mild heart failure
70. The cardiac insufficiency bisoprolol study II (CIBIS II): A randomised trial
71. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
72. Clinical trials of carvedilol in heart failure
73. Beta-adrenergic receptor blockade in chronic heart failure
74. Carvedilol for heart failure: Clinical trials in progress
75. Usefulness of beta-blocker therapy in patients with non-insulin-dependant diabetes mellitus and coronary artery disease
76. Antihypertensives and the risk of serious hypo-glycaemia in order persons using insulin or sulfonylureas
77. Tight blood pressure control and risk of macrovascular and micro-vascular complications in type 2 diabetes: UKPDS 38
78. Efficacy of atenolol and captopril in reducing risk of macrovascular and micro-vascular complications in type 2 diabetes. UKPDS 39
79. Relationship between insulin sensitivity, hyperinsulinemia, and insulin mediated sympathetic activation in normotensive and hypertensive subjects
80. Effects of insulin on vascular tone and sympathetic nervous system in NIDDM
81. Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes
82. Peripheral vascular effects of beta-blockers
83. Diuretics and b-blockers: Is there a risk for dyslipidaemia?
84. Metabolic considerations in the choice of therapy for the patient with hypertension
85. The effects of cardiovascular drugs on plasma lipids and lipoproteins
86. The effects of antihypertensive therapy on the quality of life
87. Antihypertensive therapy and quality of life: A comparison of atenolol, captopril, enalapril and propranolol
88. Quality of life on antihypertensive therapy: A randomized double-blind controlled trial of captopril and atenolol
89. Quality of life with three antihypertensive treatments: Cilazapril, atenolol and nifedipine
90. Comparison of b-blockade and ACE inhibitors in the treatment of hypertension
91. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the "treatment of mild hypertension" study
92. Quality of life in hypertensive patients treated with either carvedilol or enalapril
93. Quality of life in the management of hypertension